PMID- 36060005
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220907
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option.
PG  - 969565
LID - 10.3389/fphar.2022.969565 [doi]
LID - 969565
AB  - Purpose: The recurrent/progressive glioblastoma multiforme (GBM) carries a dismal 
      prognosis and the definitive treatment strategy has not yet been established. 
      This study aimed to assess the efficacy and safety of apatinib in 
      recurrent/progressive GBM patients. Materials and methods: The clinical data of 
      19 recurrent/progressive GBM patients who received apatinib treatment from 
      November 2015 to December 2019 at Sun Yat-sen University Cancer Center were 
      collected retrospectively in this study. Objective response rate (ORR), disease 
      control rate (DCR), progression-free survival (PFS), overall survival (OS), and 
      treatment-related adverse events (AEs) were reviewed and assessed. Results: The 
      overall ORR was 52.6%, and the DCR was 73.7%. Median PFS and OS were 5.1 and 
      10.4 months, respectively. The 6-month PFS and OS rates were 38.9% and 68.4%, 
      respectively. The 12-month PFS and OS rates were 16.7% and 36.8%, respectively. 
      The treatment-related toxicities were generally well-tolerated. The most common 
      grade 3/4 AEs were hand-foot syndrome (36.8%) and hypertension (21.1%). 
      Conclusion: Our study showed that apatinib therapy provided a better salvaging 
      option for recurrent/progressive GBM patients and the toxicity was manageable.
CI  - Copyright (c) 2022 Zhang, Du, Deng, Zheng, Yao, Wang, Yang and Wu.
FAU - Zhang, Hong-Hong
AU  - Zhang HH
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
AD  - Department of Radiation Oncology, Xiang'an Hospital of Xiamen University, Cancer 
      Research Center, School of Medicine, Xiamen University, Xiamen, China.
FAU - Du, Xiao-Jing
AU  - Du XJ
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Deng, Mei-Ling
AU  - Deng ML
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Zheng, Lie
AU  - Zheng L
AD  - Department of Medical Imaging, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Yao, Dun-Chen
AU  - Yao DC
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Wang, Zhi-Qiang
AU  - Wang ZQ
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Yang, Qun-Ying
AU  - Yang QY
AD  - Department of Neurosurgery, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
FAU - Wu, Shao-Xiong
AU  - Wu SX
AD  - Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key 
      Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer 
      Medicine, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220817
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9432461
OTO - NOTNLM
OT  - VEGFR
OT  - apatinib
OT  - efficacy
OT  - recurrent/progressive glioblastoma multiforme
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/06 06:00
MHDA- 2022/09/06 06:01
PMCR- 2022/08/17
CRDT- 2022/09/05 03:47
PHST- 2022/06/15 00:00 [received]
PHST- 2022/07/25 00:00 [accepted]
PHST- 2022/09/05 03:47 [entrez]
PHST- 2022/09/06 06:00 [pubmed]
PHST- 2022/09/06 06:01 [medline]
PHST- 2022/08/17 00:00 [pmc-release]
AID - 969565 [pii]
AID - 10.3389/fphar.2022.969565 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Aug 17;13:969565. doi: 10.3389/fphar.2022.969565. 
      eCollection 2022.